PDF Cover

Transcatheter Devices Market

The market for Transcatheter Devices was estimated at $11.1 billion in 2025; it is anticipated to increase to $19.0 billion by 2030, with projections indicating growth to around $32.5 billion by 2035.

Report ID:DS1801062
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Transcatheter Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Transcatheter Devices Market Outlook

Revenue, 2025

$11.1B

Forecast, 2035

$32.5B

CAGR, 2026 - 2035

11.3%

The Transcatheter Devices industry revenue is expected to be around $11.1 billion in 2026 and expected to showcase growth with 11.3% CAGR between 2026 and 2035. Increasing preference for minimally invasive treatments that lower the cost of treatments, the length of hospital stays and the rate of complications underlines the key role of Transcatheter Devices in modern healthcare. In the field of medical devices, cardiology and oncology treatments combined comprised 80.3% of demand. This shows how crucial it is for the industry of oncology intervention and cardiology to provide treatments for cancer and heart disease. The market for Transcatheter Devices was led by Replacement Devices which reached $5.38 billion in sales in the year 2025. This is a reflection of the strong interest shown by patients in advanced implants including transcatheter heart valves used to treat structural heart disease. Advances in technology driving the development of Transcatheter Devices are underpinned by clinical trials. As a result, these devices can be used in more situations and get licensed quicker. This is leading to their greater adoption in both existing and developing healthcare systems.

A broad range of catheter based treatments is covered by transcatheter devices, such as heart valves inserted via catheter, stent grafts, embolization systems and catheters. These systems are used to gain access to tissues which are diseased via the skin. Patients with high or moderate risk profiles are especially drawn to technology which includes faster recovery times, smaller access points, precise device placement and compatibility with radiological procedures. Among its applications are the treatment of heart disease, vascular conditions and tumours, particularly those situated in the brain. The growth in demand is currently driven by minimally invasive surgery becoming more common among younger patients and those with lower risks. Other drivers for growth include the incorporation of digital and robotic technology to improve device navigation and the adoption of more advanced drugs and materials. A further key factor is the emphasis placed on the outcomes of treatment. This information will be crucial for the long term market penetration of Transcatheter Devices.

Transcatheter Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Transcatheter Devices Market Outlook

Market Key Insights

  • The Transcatheter Devices market is projected to grow from $11.1 billion in 2025 to $32.5 billion in 2035. This represents a CAGR of 11.3%, reflecting rising demand across Cardiovascular Treatment, Congenital Heart Defect Correction, and Vascular Access Provision.

  • Leading manufacturers of heart valve systems include Abbott, Edwards Lifesciences Corporation and Boston Scientific Corporation, the latter of which are responsible for the markets competitive landscape.

  • The Transcatheter Devices market in the United States and Germany is expected to show growth at a Compound Annual Growth Rate of 8.2% to 11.9% over the period 2025 to 2030.

  • These markets Brazil, Australia and India are expected to see the most growth with an annual growth rate of between 10.8% and 14.1%.

  • The trend of moving towards less invasive treatments is expected to give a considerable boost to the development of the transcatheter devices market and could increase its value by $2 billion by the year 2030.

  • The global market for transcatheter devices is expected to rise by $21.3 billion over the period 2025 to 2035. The sector dealing with oncology and neurological applications is projected to capture a bigger share of this market.

  • The demand for minimally invasive surgical procedures is on the increase; in conjunction with advances in technology which allow for catheter based interventions, the transcatheter devices industry is set to increase by a factor of 192.2 between 2020 and 2030.

transcatheter devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Transcatheter Devices - Country Share Analysis

Opportunities in the Transcatheter Devices

The embolization and occlusion devices sector of the transcatheter sector is also growing rapidly, due to increasing medical interventions in the Asia Pacific region and other developing region's in oncology and neurovascular treatments. Growing medical investment is helping to make it possible for more hospitals to use minimally invasive embolisation for controlling tumours and preventing strokes. Between 2025 and 2030, the sector is anticipated to rise from $3.13 billion to $4.86 billion, growing at 9.2% CAGR. The neurovascular embolization segment is expected to experience the greatest growth.

Growth Opportunities in North America and Asia-Pacific

Cardiovascular applications lead Transcatheter Devices in North America, in which both structural heart interventions and transcatheter heart valves have been the main revenue producers. Neurovascular solutions have been used more in centres for the treatment of strokes. Opportunities for the company in the future exist in the expansion of the treatments target market to lower risk patients who are younger, investing in equipment for hospitals that will carry out minimally invasive surgery, and combining the technology with the use of medical robotics and imaging. The medical devices industry is fiercely competitive, with multinational firms holding onto their market position with their extensive portfolios of catheter based interventions. The smaller companies which are new and innovative are aiming for market share by targeting region's such as embolization, the left atrial appendage closure and in the field of peripheral access. The region is driven by high volumes of treatments in cardiology procedures, the availability of reimbursement for neurovascular and structural heart treatments and a considerable clinical evidence base. Several hospital networks in the region are consolidating and prefer to partner with companies which are able to offer medical devices as well as services.
The cardiovascular treatments employing catheters in the Asia Pacific region are the applications where Transcatheter Devices are most required at present. The regions with large cities are witnessing an increase in demand for catheter based cancer therapy and for interventional treatments for neurological disorders. Opportunities exist in developing heart valves, stents and embolisation products, which have had the cost engineering taken out, for regions with limited budgets. This could also include training for doctors in these region's and partnerships between the public and private sectors to allow more people to undergo minimally invasive operations in hospitals other than the best. The global market is characterised by the presence of major international companies alongside rapidly expanding regional manufacturers, with the latter competing mainly on the basis of price and customisation. This is in contrast to major international firms which differentiate their products with reference to clinical data, reliability and complex interventions involving catheters. The region is experiencing growth due to an increase in cath labs, along with an increase in the number of people suffering from heart and cancer problems. Furthermore, governments are putting money into the latest medical facilities and there is a growing acceptance by patients and clinicians of non invasive treatments that reduce recovery time and surgery risks.

Market Dynamics and Supply Chain

01

Driver: Expanding Prevalence of Cardiovascular Diseases and Growing Geriatric Population Drives Demand for Transcatheter Devices

The transcatheter devices market is also significantly propelled by the rising incidence of cardiovascular diseases (CVDs) such as aortic stenosis, coronary artery disease, and valvular disorders, particularly among older populations worldwide. As heart conditions often increase with age and lifestyle-related risk factors like hypertension and diabetes become more common, more patients require effective yet less invasive interventions than traditional open-heart surgeries, boosting demand for transcatheter aortic valve replacement and related structural heart therapies. Simultaneously, the growing geriatric population elevates the patient pool needing these advanced treatments because older patients often have also higher surgical risks, making minimally invasive approaches the preferred option in clinical settings. These demographic and disease burden trends are also key for procedural volume increases and strategic focus from market leaders such as Medtronic, Edwards Lifesciences, and Abbott.
A major driver of market growth is also the widespread shift toward minimally invasive interventions that offer faster recovery times, fewer complications, and reduced hospital stays compared with open surgeries. This trend is also supported by technological advancements such as improved imaging techniques, steerable delivery systems, and next-generation materials that enhance procedural accuracy and long-term outcomes. Innovations like advanced TAVR and TMVR devices expand clinical applications and encourage adoption among cardiologists and interventional specialists, reinforcing confidence in transcatheter therapies and widening patient access.
02

Restraint: High Cost of Transcatheter Devices and Procedure Infrastructure Limits Market Accessibility

The expensive nature of transcatheter devices and associated procedural costs remains a key restraint on market expansion. Devices such as TAVR systems and structural heart implants require advanced materials and precision engineering, which drives up the price and limits adoption in developing and cost-sensitive markets where budgets are constrained. High capital expenditure on hybrid operating rooms and sophisticated imaging systems further deters smaller hospitals and clinics from offering these procedures, slowing revenue growth and reducing patient access despite rising clinical need. 
03

Opportunity: Rapidly expanding transcatheter replacement devices market for structural heart disease in aging global cardiac populations and Accelerating adoption of transcatheter repair devices for high-surgical-risk mitral patients in advanced healthcare systems

There is growing demand for the transcatheter devices industry as a result of interventional cardiologys shift towards minimal invasive treatments for structural heart conditions. A significant role has been assumed by replacement devices with this in mind, notably the transcatheter heart valves. These medical devices are of great benefit to elderly patients with a heightened surgical risk who cannot have open heart surgery. The market is projected to rise from $5.38 billion to $9.18 billion by the year 2030; this represents a compound annual growth rate of 11.3%. Devices to replace the aortic and mitral valves will be responsible for the majority of the growth in revenue generated by heart valve replacements worldwide.
Treatment of mitral regurgitation and tricuspid regurgitation is being transformed through the use of transcatheter mitral and tricuspid repair systems. The trend in cardiology is towards less invasive procedures, particularly for patients who have a high surgical risk. As a result, there is growing need for annuloplasty based transcatheter devices and edge to edge repair systems. The sector is predicted to grow from $2.63 billion in 2025 to $4.97 billion by 2030, with the fastest CAGR of 13.61% during this period. Mitral repair through a catheter will experience the strongest growth, largely due to collaborations between imaging centres, heart doctors and the manufacturers of catheters.
04

Challenge: Stringent Regulatory Approvals and Training Gaps Delay Innovation and Adoption

The transcatheter devices market faces significant regulatory challenges that slow the approval and commercialization of new technologies, requiring extensive clinical trials and long follow-up data before clearance. This limits the pace at which manufacturers can bring next-generation devices to regional markets, increasing development costs and delaying competitive differentiation. Additionally, the need for highly skilled interventional cardiologists and multidisciplinary teams to perform complex procedures restricts adoption in many regions, creating bottlenecks that dampen procedure volumes and market momentum. 

Supply Chain Landscape

1

Cardiovascular Components

DSM BiomedicalGore MedicalTeleflex
2

Transcatheter Devices Manufacturing

Edwards Lifesciences CorporationAbbottMedtronic
3

Minimally Invasive Distribution

Cardinal HealthOwens & MinorMedline Industries
4

Structural Heart Applications

HospitalsCardiac catheterization laboratoriesAmbulatory surgical centers
Transcatheter Devices - Supply Chain

Use Cases of Transcatheter Devices in Cardiovascular Treatment & Vascular Access Provision

Cardiovascular Treatment : In cardiovascular treatment, transcatheter devices such as transcatheter aortic valve replacement (TAVR) systems, transcatheter mitral valve repair (TMVR) devices, and catheters and stents are widely used to manage a range of cardiac conditions including aortic stenosis, mitral regurgitation and coronary artery disease without open-heart surgery. These minimally invasive tools, deployed via femoral or transseptal access, reduce perioperative risk and shorten hospital stays compared with traditional surgery, making them preferred in cardiac catheterization labs and hospitals. Key market players such as Medtronic, Abbott Laboratories, Edwards Lifesciences and Boston Scientific lead with robust portfolios that emphasize procedural safety, precision delivery, and durable clinical outcomes in structural heart care.
Congenital Heart Defect Correction : For congenital heart defect correction, transcatheter devices including septal occluders, PDA closure devices and specialized pediatric catheters enable percutaneous closure of defects like atrial septal defects and patent ductus arteriosus that traditionally required open surgery. These devices facilitate rapid healing, reduce trauma, and lower complication rates, enhancing quality of life for both pediatric and adult patients. Hospitals and pediatric cardiac centers increasingly adopt solutions from Abbott Laboratories, Medtronic, Boston Scientific and Edwards Lifesciences, which combine advanced imaging guidance with precise anatomical fit, improving procedural success and long-term outcomes in congenital interventions.
Vascular Access Provision : In vascular access provision, transcatheter devices such as vascular introducer sheaths, guidewires and closure systems are critical for establishing percutaneous entry points in minimally invasive procedures. These devices support reliable access to the arterial or venous system, enabling subsequent deployment of therapeutic tools like stents or occluders with reduced bleeding and faster recovery. End users include cardiac and interventional radiology units, ambulatory surgical centers and specialty clinics. Companies like Terumo, Merit Medical, Medtronic and Boston Scientific focus on enhanced device ergonomics and safety features that optimize access stability and procedural efficiency in complex care pathways.

Recent Developments

The transcatheter devices market is advancing with strategic focus on structural heart repair and minimally invasive therapies, driven by innovations in transcatheter valve systems, catheter-based closure devices, and delivery platforms. A key trend is the expansion of indications from high-risk patients to intermediate and low-risk groups, supported by real-world clinical evidence and improved imaging guidance technologies. This shift is boosting procedure volumes, enhancing market adoption, and reinforcing competitive positioning among leading manufacturers.

May 2025 : Edwards Lifesciences’ SAPIEN 3 transcatheter aortic valve replacement platform gained U.S. FDA approval for use in asymptomatic severe aortic stenosis patients, broadening clinical adoption beyond symptomatic cases and reinforcing its leadership in minimally invasive valve therapies.
March 2025 : Abbott disclosed long-term data from its TRILUMINATE Pivotal trial showing that the TriClip transcatheter edge-to-edge repair system significantly improved outcomes and reduced hospitalizations in tricuspid regurgitation patients, strengthening its clinical evidence base.
November 2023 : Meril Life Sciences signed an agreement with Japan Lifeline to promote its Myval Octacor transcatheter heart valve in Japan, supporting geographic expansion for its transcatheter valve platform. 

Impact of Industry Transitions on the Transcatheter Devices Market

As a core segment of the Medical Device industry, the Transcatheter Devices market develops in line with broader industry shifts. Over recent years, transitions such as Transition to Minimally Invasive Procedures and Expansion from High-Risk Patients to Broader Patient Populations have redefined priorities across the Medical Device sector, influencing how the Transcatheter Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition to Minimally Invasive Procedures

The trend towards minimally invasive procedures is driving the development of the transcatheter devices market. Catheter based treatments are increasingly preferred over traditional open heart surgery in cardiology. The trend in the cardiology devices market is being influenced by the fact that catheter based technologies cause less trauma, allow patients to be discharged from hospital quicker and enable quicker recovery times. As a result, the market is predicted to rise by a further $2 billion by 2030. The competitive landscape is undergoing a significant transformation, necessitating the enhancement of R&D in the development of advanced transcatheter technologies, improved product delivery and durability and the expansion of uses for interventional cardiology. With a growing emphasis on better results for patients and a need for healthcare cost savings, major hospitals are adopting Transcatheter devices. These are used as an alternative to conventional open heart surgery and are key to their long term growth through innovation.
02

Expansion from High-Risk Patients to Broader Patient Populations

The transcatheter devices market is undergoing a pivotal transition as therapies expand from high-risk and inoperable patients to intermediate and low-risk populations. Advances in device durability, miniaturized delivery systems, and long-term clinical evidence have increased physician confidence, enabling earlier intervention and broader patient eligibility. This shift is reshaping healthcare reimbursement frameworks, with payers accommodating higher procedure volumes and shorter hospital stays, while supporting the growth of outpatient and ambulatory cardiac care models. The transition also stimulates innovation across associated industries, including vascular access devices, closure systems, and post-procedure imaging and remote monitoring technologies. As procedure volumes rise, preventive cardiology and follow-up care solutions gain traction, reinforcing sustained growth across the wider interventional cardiology ecosystem.